Xenon Pharmaceuticals Inc. (XENE) Return on equity 2016–2025
Xenon Pharmaceuticals Inc. (XENE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-59.5%FY2025 · since FY2016: -36.0% → -59.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -59.5% | -28.4 pp |
| FY2024 | -31.0% | -11.4 pp |
| FY2023 | -19.7% | -2.3 pp |
| FY2022 | -17.4% | -3.0 pp |
| FY2021 | -14.3% | +2.5 pp |
| FY2020 | -16.8% | +28.4 pp |
| FY2019 | -45.2% | — |
| FY2017 | -85.4% | -49.5 pp |
| FY2016 | -36.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice